Involvement of transient receptor potential vanilloid type 1 channels in the pro-convulsant effect of anandamide in pentylenetetrazole-induced seizures

Epilepsy Research

Volumn 100, Issue 1-2, 2012, Pages 113-124

  Manna, Shyamshree S S ^a   Umathe, Sudhir N ^a  

^a RTM NAGPUR UNIVERSITY   (India)

Author keywords

AM404; Capsaicin; Capsazepine; CB1 receptors; FAAH inhibitor; Glutamate

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CAPSAICIN; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; VANILLOID RECEPTOR 1;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; GRAND MAL SEIZURE; LATENT PERIOD; LOW DRUG DOSE; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCONVULSANT ACTIVITY; SEIZURE; TONIC CLONIC SEIZURE;

ANIMALS; ARACHIDONIC ACIDS; CONVULSANTS; ENDOCANNABINOIDS; MALE; MICE; PENTYLENETETRAZOLE; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; SEIZURES; TRPV CATION CHANNELS;

EID: 84861528229     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.02.003     Document Type: Article

References (70)

1. Alger B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. 2002, 68:247-286.
2. Alter B.J., Gereau R.W. Hotheaded: TRPV1 as mediator of hippocampal synaptic plasticity. Neuron 2008, 57:629-631.
3. Ameri A., Simmet T. Effects of 2-arachidonylglycerol, an endogenous cannabinoid, on neuronal activity in rat hippocampal slices. Naunyn-Schmiedebergs Arch. Pharmacol. 2000, 361:265-272.
4. Andersson D.A., Adner M., Hogestatt E.D., Zygmunt P.M. Mechanisms underlying tissue selectivity of anandamide and other vanilloid receptor agonists. Mol. Pharmacol. 2002, 62:705-713.
5. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997, 277:1094-1097.
6. Bengzon J., Söderström S., Kokaia Z., Kokaia M., Ernfors P., Persson H., Ebendal T., Lindvall O. Widespread increase of nerve growth factor protein in the rat forebrain after kindling-induced seizures. Brain Res. 1992, 587:338-342.
7. Bhaskaran M.D., Smith B.N. Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy. Exp. Neurol. 2010, 223:529-536.
8. Bortolato M., Campolongo P., Mangieri R.A., Scattoni M.L., Frau R., Trezza V., La Rana G., Russo R., Calignano A., Gessa G.L., Cuomo V., Piomelli D. Anxiolytic like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 2006, 31:2652-2659.
9. Chemin J., Monteil A., Perez-Reyes E., Nargeot J., Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 2001, 20:7033-7040.
10. Clement A.B., Hawkins E.G., Lichtman A.H., Cravatt B.F. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 2003, 23:3916-3923.
11. Cristino L., de Petrocellis L., Pryce G., Baker D., Guglielmotti V., Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006, 139:1405-1415.
12. De Petrocellis L., Bisogno T., Davis J.B., Pertwee R.G., Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 2000, 483:52-56.
13. De Petrocellis L., Davis J.B., Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid vr1 receptors. FEBS Lett. 2001, 506:253-256.
14. Deadwyler S.A., Hampson R.E., Bennett B.A., Edwards T.A., Mu J., Pacheco M.A., Ward S.J., Childers S.R. Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptors Channels 1993, 1:121-134.
15. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003, 83:1017-1066.
16. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:1932-1936.
17. Hermann H., De Petrocellis L., Bisogno T., Schiano Moriello A., Lutz B., Di Marzo V. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor mediated response. Cell. Mol. Life Sci. 2003, 60:607-616.
18. 1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur. Neuropsychopharmacol. 2005, 15:593-599.
19. Ho W.S., Barrett D.A., Randall M.D. 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 2008, 155:837-846.
20. 1 receptor inverse agonist AM251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. Behav. Brain Res. 2008, 193:298-305.
21. Howlett A.C., Scott D.K., Wilken G.H. Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies. Biochem. Pharmacol. 1989, 38:3297-3304.
22. Ji R.R., Samad T.A., Jin S.X., Schmoll R., Woolf C.J. P38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002, 36:57-68.
23. Jin Y.H., Bailey T.W., Li B.Y., Schild J.H., Andresen M.C. Purinergic and vanilloid receptor activation releases glutamate from separate cranial afferent terminals in nucleus tractus solitarius. J. Neurosci. 2004, 24:4709-4717.
24. Karler R., Cely W., Turkanis S.A. The anticonvulsant activity of cannabidiol and cannabinol. Life Sci. 1973, 13:1527-1531.
25. Karler R., Cely W., Turkanis S.A. Anticonvulsant properties of delta 9-tetrahydrocannabinol and other cannabinoids. Life Sci. 1974, 15:931-947.
26. Kupferberg H. Animal models used in the screening of antiepileptic drugs. Epilepsia 2001, 42:7-12.
27. Leach M.J., Marden C.M., Miller A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia 1986, 27:490-497.
28. Leite J.P., Neder L., Arisi G.M., Carlotti C.G., Assirati J.A., Moreira J.E. Plasticity, synaptic strength, and epilepsy: what can we learn from ultrastructural data?. Epilepsia 2005, 46:134-141.
29. Li D.P., Chen S.R., Pan H.L. VR1 receptor activation induces glutamate release and postsynaptic firing in the paraventricular nucleus. J. Neurophysiol. 2004, 92:1807-1816.
30. Li H.B., Mao R.R., Zhang J.C., Yang Y., Cao J., Xu L. Antistress effect of TRPV1 channel on synaptic plasticity and spatial memory. Biol. Psychiatry 2008, 64:286-292.
31. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res. 1991, 8:171-189.
32. Ludányi A., Eross L., Czirják S., Vajda J., Halász P., Watanabe M., Palkovits M., Maglóczky Z., Freund T.F., Katona I. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J. Neurosci. 2008, 28:2976-2990.
33. Maccarrone M., Lorenzon T., Bari M., Melino G., Finazzi-Agra A. Anandamide induces apoptosis in human cells via vanilloid receptors-evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 2000, 275:31935-31938.
34. Maione S., Cristino L., Migliozzi A.L., Georgiou A.L., Starowicz K., Salt T.E., Di Marzo V. TRPV1 channels control synaptic plasticity in the developing superior colliculus. J. Physiol. 2009, 87:2521-2535.
35. Mang C.F., Erbelding D., Kilbinger H. Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br. J. Pharmacol. 2001, 134:161-167.
36. Marsch R., Foeller E., Rammes G., Bunck M., Kossl M., Holsboer F., Zieglgansberger W., Landgraf R., Lutz B., Wotjak C.T. Reduced anxiety, conditioned fear, and hippocampal long term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J. Neurosci. 2007, 27:832-839.
37. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutiérrez S.O., van der Stelt M., López-Rodriguez M.L., Casanova E., Schütz G., Zieglgänsberger W., Di Marzo V., Behl C., Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302:84-88.
38. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgänsberger W., Di Marzo V., Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
39. Meador K.J. The basic science of memory as it applies to epilepsy. Epilepsia 2007, 48:23-25.
40. Meldrum B.S. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994, 44:S14-S23.
41. Mezey E., Tóth Z.E., Cortright D.N., Arzubi M.K., Krause J.E., Elde R., Guo A., Blumberg P.M., Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:3655-3660.
42. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Drago F., Di Marzo V. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009, 34:593-606.
43. Mitchell V.A., Greenwood R., Jayamanne A., Vaughan C.W. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Clin. Exp. Pharmacol. Physiol. 2007, 34:1186-1190.
44. Naderi N., Ahmad-Molaei L., Aziz Ahari F., Motamedi F. Modulation of anticonvulsant effects of cannabinoid compounds by GABA-A receptor agonist in acute pentylenetetrazole model of seizure in rat. Neurochem. Res. 2011, 36:1520-1525.
45. Naderi N., Aziz Ahari F., Shafaghi B., Najarkolaei A.H., Motamedi F. Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J. Neural Transm. 2008, 115:1501-1511.
46. Nagy I., Ahluwalia J., Urban L. Dual effect of anandamide on nociceptive primary sensory neurones. Soc. Neurosci. Abstr. 2002, 2002:65.
47. Paxinos G., Franklin R.B.J. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego.
48. 1 receptors. Life Sci. 2005, 76:1307-1324.
49. Pingle S.C., Matta J.A., Ahern G.P. Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb. Exp. Pharmacol. 2007, 179:155-171.
50. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., Dasse O., Monaghan E.P., Parrott J.A., Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006, 12:21-38.
51. Roberts J.C., Davis J.B., Benham C.D. [3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res. 2004, 995:176-183.
52. Ross R.A. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 2003, 140:790-801.
53. Ross R.A., Gibson T.M., Brockie H.C., Leslie M., Pashmi G., Craib S.J., Di Marzo V., Pertwee R.G. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J. Pharmacol. 2001, 132:631-640.
54. Rubino T., Realini N., Castiglioni C., Guidali C., Viganó D., Marras E., Petrosino S., Perletti G., Maccarrone M., Di Marzo V., Parolaro D. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb. Cortex 2008, 18:1292-1301.
55. Santos J.G., Do Monte F.H., Russi M., Agustine P.E., Lanziotti V.M. Proconvulsant effects of high doses of venlafaxine in pentylenetetrazole-convulsive rats. Braz. J. Med. Biol. Res. 2002, 35:469-472.
56. Sasamura T., Sasaki M., Tohda C., Kuraishi Y. Existence of capsaicin-sensitive glutamatergic terminals in rat hypothalamus. Neuroreport 1998, 9:2045-2048.
57. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 1996, 16:4322-4334.
58. Shen M., Thayer S.A. Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol. Pharmacol. 1999, 55:8-13.
59. Siekevitz P. The postsynaptic density: a possible role in long-lasting effects in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:3494-3498.
60. Smart D., Jonsson K.O., Vandevoorde S., Lambert D.M., Fowler C.J. 'Entourage' effects of n-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br. J. Pharmacol. 2002, 136:452-458.
61. Starowicz K., Cristino L., Di Marzo V. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr. Pharm. Des. 2008, 14:42-54.
62. Starowicz K., Maione S., Cristino L., Palazzo E., Marabese I., Rossi F., de Novellis V., Di Marzo V. Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J. Neurosci. 2007, 27:13739-13749.
63. Starowicz K., Nigam S., Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol. Ther. 2007, 114:13-33.
64. Sulcova E., Mechoulam R., Fride E. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 1998, 59:347-352.
65. Tóth A., Boczán J., Kedei N., Lizanecz E., Bagi Z., Papp Z., Edes I., Csiba L., Blumberg P.M. Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res. Mol. Brain Res. 2005, 135:162-168.
66. Umathe S.N., Vaghasiya J.M., Jain N.S., Dixit P.V. Neurosteroids modulate compulsive and persistent behavior in rodents: implications for obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1161-1166.
67. Wallace M.J., Martin B.R., DeLorenzo R.J. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur. J. Pharmacol. 2002, 452:295-301.
68. Wallace M.J., Wiley J.L., Martin B.R., DeLorenzo R.J. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 2001, 428:51-57.
69. Xing J., Li J. TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J. Neurophysiol. 2007, 97:503-511.
70. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sørgård M., Di Marzo V., Julius D., Högestätt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.